AdvaMed® Medical Imaging™ Standards

Millions of patients’ lives are improved every day because of advancements in medical technology. But too often, gaps in coverage and access prevent patients from benefiting from the safe, effective, and innovative technologies that can help detect disease earlier, improve treatment, and support better outcomes. 

That is why AdvaMed’s 2026 Patients First Agenda focuses on supporting policies that put patients at the center of health care. Across the country, AdvaMed works alongside patient advocacy group partners to help address gaps in access and coverage for critical medical technologies and bring innovative care to patients and families when they need it most.

BOSTON, MA, UNITED STATES, May 26, 2026 /EINPresswire.com/ — UltraSight™, a leader in AI-guided cardiac imaging, today announced publication of a multicenter peer-reviewed study in European Heart Journal – Digital Health showing clinicians with no prior ultrasound experience achieved diagnostic-quality cardiac ultrasound images in 97.7% of cases after a single day of AI-guided training.

BOSTON, MA, UNITED STATES, May 19, 2026 /EINPresswire.com/ — UltraSight™, a leader in AI-guided cardiac imaging, today announced the appointment of Rick Geoffrion as Chairman of the Board. Mr. Geoffrion brings more than 35 years of medical technology leadership experience, including more than 30 years in the cardiovascular space, spanning interventional cardiology, circulatory support, structural heart, and medical device commercialization.

Learn how AdvaMed’s standards are shaping innovation and improving regulatory efficiency across the medical technology industry.

WASHINGTON—AdvaMed® announced today that nominations for its 2025 Lifetime Achievement Award as well as the AdvaMedDx Lifetime of Leadership & Service Award and theAdvaMed® Imaging Röntgen Award are open through April 10. All three of these annual awards will be presented during The MedTech Conference, Oct.18-21, 2026, in Boston. 

TORONTO and DALLAS, March 3, 2026 /PRNewswire/ – Perimeter Medical Imaging AI, Inc. (TSXV: PINK) (OTCQX: PYNKF) (“Perimeter” or the “Company”), a commercial-stage medical technology company, announced today that it has received U.S. Food and Drug Administration (“FDA”) premarket approval (“PMA”) for Claire™ (formerly the Perimeter OCT B-Series with ImgAssist AI 2.0), the first AI-enabled imaging device approved in the United States for intraoperative breast cancer margin assessment. The technology received Breakthrough Device designation from the FDA and is designed to enhance surgeons’ ability to detect difficult-to-see cancer during breast-conserving surgery and potentially reduce the need for re-operations.

WASHINGTON, D.C.—AdvaMed, the world’s largest trade association representing medical technology innovators, announced that its Medical Device Submissions Workshop Series (February 23-27 in Washington, D.C.) has been officially approved for RAC recertification credits by the Regulatory Affairs Professionals Society (RAPS).

In a new video developed in partnership with Patients Rising, AdvaMed’s Peter Weems, Vice President of Imaging Government Affairs and Policy Strategy, explains why the Health Tech Investment Act is critical to expanding patient access to FDA-authorized AI-enabled medical devices.